-
A recent retrospective observational study in diabetic men with prostate cancer suggests that poor glycemic control before radical prostatectomy increases the risk of later progression, including metastasis.
-
HIV-negative men who have sex with men (MSM), who use PrEP, are significantly more likely to have other sexually transmitted diseases.
-
Researchers have tested another antibody against HIV that suppressed the further proliferation of the virus in infected individuals.
-
Acellular vaccines against Bordetella pertussis protect about 75% of vaccinated children between the ages of five and nine years. Approximately 65% of these children are vaccinated for five years. However, it is not possible to eradicate the disease.
-
A current study shows that the pathogen spectrum has changed in recent years and that more antifungal resistance is occurring.
-
According to the World Health Organization (WHO), digital medicine is an indispensable component of future health care. For this reason, the WHO recently published the first guidelines on the use of digital technologies in the health sector.
-
The European Society for Medical Oncology (ESMO) has updated its treatment guidelines for prostate cancer on the basis of the new data from the STAMPEDE and HORRAD trials.
-
According to a recent study, rivaroxaban did not significantly lower the incidence of venous thromboembolism (VTE) or death from VTE in high-risk outpatient tumor patients.
-
A new meta-analysis sheds doubts again on its harmlessness. People who were exposed to very high concentrations of glyphosate had up to 41% more risk of developing non-Hodgkin's lymphoma.
-
The European Medicines Agency (EMA) has suspended cough medicine containing fenspiride with immediate effect. This is due to repeated reports from studies showing that ingestion of the active substance could impair cardiac function.
-
The combination of pembrolizumab and axitinib provided longer overall survival and progression-free survival with a high response rate in patients with non-pretreated mRCC.
-
Differences between men and women may be highly probably therapeutically significant. Particularly in the field of tumor medicine, risks and opportunities depend on the respective sex.
-
In recent years, immunotherapies with checkpoint inhibitors have significantly improved the therapeutic options for numerous tumor diseases. Even if phase III data are still outstanding for the treatment of hepatocellular carcinoma (HCC), there are new data from smaller study cohorts.
-
Phase-II study proves the efficacy of the dual PPARα/δ agonist elafibranor as additional therapy to ursodeoxycholic acid in the treatment of primary biliary cholangitis (PBC).
-
One strategy that has proven promising in Phase II is the activation of the intracellular receptor RIG-I to improve the immune response to the virus and to eliminate HBsAg in combination with antiviral therapy.
-
A new and currently experimental approach in the development of effective therapies for chronic hepatitis B is the inhibition of the HBV core protein. A study presented at ILC 2019 demonstrated the strong antiviral efficacy of this approach.
-
While the cure of hepatitis C today is not a medical problem for almost all patients, but at most, a health policy problem, the elimination or at least drug-free control of the HB virus can still only be achieved in a minority of chronically infected patients.
-
Even under a cutoff of less than 2000 IU/ml HBV DNA, infected patients have an increased risk of developing hepatocellular carcinoma. This is probably due to the integration of the hepatitis B virus (HBV) into the human genome.
-
A study from Great Britain shows that in a population-based cohort, almost every fifth person examined had a fatty liver with an average age of 24 years. In addition, many patients had already developed liver fibrosis.
-
Today, almost all HCV-infections can be successfully treated in clinical routine - even those patients who have not responded to pre-therapies or who have shown failure in therapy.
